The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the expanded approval of Kyowa Kirin Co. Ltd.’s Crysvita (burosumab) to include older adolescents and adults living with the rare disease X-linked hypophosphatemia.

Shares of Ultragenyx sharply climbed after the company announced positive results from its Phase III study of burosumab in adults with X-linked hypophosphatemia (XLH).